Scienmag

DECEMBER 27, 2021

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate.

Antibody 73

Antibody Scientist Protein Vaccine 73

Pharmaceutical Technology

DECEMBER 5, 2022

With the establishment of this Translational Science Hub, Queensland is set to become an international messenger ribonucleic acid (mRNA) vaccine hub. With an initial focus on enchaining mRNA technology and developing a vaccine for Chlamydia, the research at the hub is anticipated to commence in the first quarter of next year.

Research 246

Research Gene Therapy Vaccine Vaccination 246

pharmaphorum

SEPTEMBER 14, 2020

AstraZeneca has resumed UK trials for its coronavirus vaccine, after the country’s medicines regulator gave the all-clear following a safety scare. Good news for everyone the Oxford vaccine trials are back up and running. We will back our scientists to deliver an effective vaccine as soon as safely possible [link].

Vaccine 104

Vaccine Vaccination Trials Protein 104

pharmaphorum

JANUARY 20, 2021

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. VOC 202012/01 has an unusually high number of genetic changes however, with 10 mutations affecting the spike protein. lineage or VOC 202012/01.

Vaccine 98

Vaccine Vaccination Antibody Protein 98

pharmaphorum

SEPTEMBER 17, 2020

US medical experts are reportedly concerned that a neurological side effect picked up in AstraZeneca’s closely-watched COVID-19 vaccine trial could compromise the whole project, as the FDA weighs whether to give the go ahead for US studies to resume. The post US experts stress over safety of AZ’s COVID-19 vaccine appeared first on.

Vaccine 105

Vaccine Vaccination Trials Medicine 105

pharmaphorum

NOVEMBER 25, 2022

Scientists in the US say they have developed an mRNA-based vaccine that encompasses all 20 known subtypes of influenza that could form the basis of a future universal jab. The goals of the programme are also similar to those in COVID vaccine development.

Vaccine 105

Vaccine Vaccination Research Immune Response 105

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . The post Altimmune ditches nasal COVID vaccine on weak trial data appeared first on.

Vaccine 98

Vaccine Vaccination Trials Immune Response 98

Pharmaceutical Technology

APRIL 20, 2023

In addition to new regulatory functionalities, this feature may result in stronger and more durable protein expression. Circio aims to develop new circRNA medicines initially for cancer, then plans to expand rapidly into vaccines and gene therapy.

Gene Therapy 240

Gene Therapy RNA Gene Development 240

Medical Xpress

DECEMBER 1, 2022

In 2021, a group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate containing an adjuvant, a substance that enhances immune responses, elicited durable neutralizing antibody responses to SARS-CoV-2 (..)

Vaccine 74

Vaccine Vaccination Immune Response Containment 74

pharmaphorum

NOVEMBER 9, 2020

As the death toll from COVID19 inexorably mounts, Pfizer and BioNTech have announced that their COVID-19 vaccine candidate is more than 90% effective at countering the disease in an interim analysis. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule.

Vaccine 98

Vaccine Vaccination Clinical Trials Clinical Trials 98

pharmaphorum

NOVEMBER 10, 2021

After being hailed as a triumph of public-private drug development, Moderna’s partnership with the US government on its COVID-19 vaccine looks like it may descend into acrimony. The patent has been filed but not yet awarded.

Vaccine 105

Vaccine Vaccination Scientist Protein 105

pharmaphorum

JULY 14, 2021

AstraZeneca and Johnson & Johnson are both exploring ways to modify their COVID-19 vaccines to minimise the risk of severe blood clotting reactions that are seen – albeit rarely – in some people receiving the jabs. Its guideline is due to be published before the end of this month.

Vaccine 116

Vaccine Vaccination Immune Response Protein 116

The Pharma Data

DECEMBER 7, 2020

7, 2020 — Scientists say they may be getting closer to creating a universal flu vaccine. In an early-stage clinical trial with 65 volunteers in the United States, an experimental vaccine triggered strong immune responses to a wide range of flu virus strains and subtypes. MONDAY, Dec.

Vaccine 52

Vaccine Vaccination Scientist Immune Response 52

Scienmag

OCTOBER 30, 2020

Vaccine protects animals against tick-borne Powassan virus, an emerging infectious disease Credit: The Wistar Institute PHILADELPHIA — (Oct. A rapidly reemerging tick-borne disease, POWV has been reported […].

DNA 61

DNA Vaccine Vaccination Protein 61

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants. bioRxiv [Preprint]. 2021 Apr 8:2021.04.08.438884.

Protein 52

Protein Vaccine Vaccination Antibody 52

XTalks

SEPTEMBER 8, 2020

The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus. AMRI is proud to partner with AstraZeneca in pursuit of a vaccine that could protect people against the coronavirus pandemic,” said John Ratliff, CEO of AMRI, in a statement.

Manufacturing 83

Manufacturing Vaccine Vaccination Allergies 83

pharmaphorum

DECEMBER 21, 2020

Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge.

Vaccine 111

Vaccine Vaccination Doctors Doctor 111

XTalks

OCTOBER 21, 2020

The answer may lie in the genetic code of the virus, which scientists at Duke University have found contains several silent mutations that affect protein folding. The researchers focused on the spike proteins that protrude from the surface of the coronavirus, which are responsible for viral attachment and entry into host cells.

RNA 98

RNA Protein Genome Genomics 98

Scienmag

SEPTEMBER 18, 2020

Antibody-like proteins that capture and neutralize SARS-CoV-2 Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus – 4 of which also exhibited neutralizing activity – within 4 days, according to a new study.

Protein 53

Protein Antibody In-Vitro Scientist 53

XTalks

FEBRUARY 19, 2024

Moderna has been testing an experimental mRNA vaccine aimed at combating the human cytomegalovirus (CMV), which poses significant health risks to newborns and immunocompromised patients. The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine.

Vaccine 59

Vaccine Vaccination Trials Clinical Trials 59

The Pharma Data

FEBRUARY 12, 2022

The COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the base of its spike protein that is found also on closely related coronaviruses, according to a new study from Scripps Research. In the new work, they mapped at atomic scale the site, or “epitope,” to which the antibody binds on the SARS-Cov-2 spike protein.

Scientist 52

Scientist Antibody Protein Vaccine 52

pharmaphorum

MARCH 19, 2021

Now the Ireland-based firm said that early data from studies shows the system can detect and identify the COVID virus S-Protein in quantities at 40 femtograms per millilitre at close to 100% specificity. A femtogram is 0.000000000000000001 kilograms.

Contamination 145

Contamination Clinical Trials Clinical Trials Protein 145

Scienmag

MAY 27, 2021

A digital tool that will make it cheaper, safer and faster to develop new medicines is being rolled out by scientists from the University of Bath in the UK.

Protein 52

Protein Scientist Medicine Development 52

XTalks

NOVEMBER 27, 2021

So far scientists and health officials have said it’s unclear whether Omicron is more transmissible than other variants such as Delta or the original version of the coronavirus. Related: FDA Authorizes Pfizer/BioNTech COVID-19 Vaccine for Kids 5 to 11. It is also the protein that the current COVID-19 vaccines target.

Vaccine 97

Vaccine Vaccination Protein Scientist 97

pharmaphorum

FEBRUARY 1, 2022

1 strain, and there is somewhat conflicting evidence on its ability to evade the protection from vaccines, according to new studies. That increase was seen regardless of the vaccination status of the secondary cases, and there was an increased risk of spread within vaccinated households with BA.2 The new BA.2 1 and 70% for BA.2

Vaccine 98

Vaccine Vaccination Scientist Genome 98

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Vaccination Protein Immune Response 52

pharmaphorum

JANUARY 22, 2021

According to the US biopharma company, genetic analyses of publicly available sequences for the new variants of SARS-CoV-2 suggest the mutations in the viral spike protein that have made them more transmissible shouldn’t affect the way Veklury (remdesivir) works. The UK strain – known as B.1.1.7

In-Vitro 141

In-Vitro RNA Licensing Licensing 141

XTalks

JANUARY 11, 2023

The new subvariant has also been dubbed “Kraken” by some scientists. Importantly, preliminary data shows that bivalent COVID-19 vaccines that target the parent strain of Omicron should provide protection against XBB.1.5 on the horizon as scientists say the virus appears to be rapidly evolving , mutating faster than most viruses.

Scientist 98

Scientist Vaccine Vaccination Genetics 98

pharmaphorum

NOVEMBER 2, 2020

With a collective sense of uncertainty, many are pinning their hopes on a vaccine and treatment, and sophisticated technology could help speed up the process of finding an effective medicine. Scientists are using AI to sift through existing literature on a disease and study its disease’s structure.

Nurses 132

Nurses Scientist Clinical Trials Clinical Trials 132

Pharmaceutical Technology

JULY 22, 2022

In addition, immunity against the infection is found to wane for both previously infected individuals and the vaccinated. Muge Cevik, a clinical scientist, shared an article around the mystery of viral hepatitis cases in children. Measles is highly contagious and therefore is more visible when vaccine levels decline, the article noted.

Vaccine 130

Vaccine Vaccination Life Science Immune Response 130

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award. To foster young talent development in the feline health research community. References.

Scientist 52

Scientist Immune Response Antibody Development 52

Scienmag

OCTOBER 23, 2020

The technique should help in the design of vaccines against HIV, SARS-CoV-2 and other viruses that cloak their outer proteins with sugars to evade antibodies.

Protein 61

Protein Antibody Scientist Vaccine 61

The Pharma Data

JANUARY 21, 2021

22, 2021 — Everyone has heard the scary reports about the new, more infectious coronavirus variants that are circulating in countries around the world, but scientists aren’t pushing the panic button at this point. Because the new COVID-19 vaccines should still work on these viral interlopers. FRIDAY, Jan.

Vaccine 52

Vaccine Vaccination Protein Immune Response 52

pharmaphorum

DECEMBER 2, 2021

Health and Social Care Secretary, Sajid Javid, announced the move as researchers race to uncover the effect of existing vaccines on the Omicron variant, which was first identified by scientists in South Africa. Up to 60 million doses of Moderna’s vaccine, which may include authorised booster doses, were given the green light.

Vaccine 52

Vaccine Vaccination Protein Scientist 52

pharmaphorum

JANUARY 26, 2023

A 2022 study from the Royal College of Physicians and British Pharmacological Society demonstrated the potential of pharmacogenomics, with scientists identifying the genetic cause behind an individual’s drug response for over forty medicines. Just one mutation can lead to a complete change in protein formation.

Genome 129

Genome Genomics Genome Project Genetics 129

pharmaphorum

MARCH 9, 2021

ExeVir has been working with scientists at Vlaams Instituut voor Biotechnologie (VIB)-UGent Center for Medical Biotechnology and the big pharma UCB on the project. The company announced preprint publication of research by VIB scientists, demonstrating highly potent viral neutralising activity.

Antibody 98

Antibody Life Science Scientist Development 98

The Pharma Data

AUGUST 9, 2021

Research by Lancaster University scientists to create a COVID-19 vaccine which can be administered through the nose has taken a significant step forward. The pre-clinical animal trials of the intranasal vaccine showed a reduction in both the impact of the disease itself and transmission of the virus.

Vaccine 52

Vaccine Vaccination Immune Response Scientist 52